

Supporting Information

Supplementary results

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix to: Hengel B, McManus H, Monaghan R, et al. Notification rates for syphilis in women of reproductive age and congenital syphilis in Australia, 2011–2021: a retrospective cohort analysis of national notifications data. *Med J Aust* 2024; doi: 10.5694/mja2.52388.

| | Annual notification rate (per 100,000 population) | | |
|--|---|------------------------|--|
| Indigenous status/age group/year | Actual Fitted (95% confidence interval) | | |
| Aboriginal or Torres Strait Islander women, 15-24 years | | | |
| 2011 | 31.38 | 23.12 (15.92–30.32) | |
| 2012 | 18.91 | 32.17 (23.81–40.53) | |
| 2013 | 26.96 | 44.77 (35.27–54.26) | |
| 2014 | 59.50 | 62.29 (51.65–72.93) | |
| 2015 | 118.91 | 86.68 (74.37–98.99) | |
| 2016 | 128.36 | 120.61 (104.46–136.76) | |
| 2017 | 211.78 | 167.83 (142.66–193.00) | |
| 2018 | 212.24 | 233.53 (190.57–276.49) | |
| 2019 | 267.70 | 324.95 (250.88–399.03) | |
| 2020 | 229.58 | 230.45 (144.95–315.96) | |
| 2020.5 | 281.98 | 260.90 (198.01–323.78) | |
| 2021 | 287.30 | 307.16 (229.61–384.70) | |
| Aboriginal or Torres Strait Islander women, 25-34 years | | | |
| 2011 | 120.68 | 82.41 (62.85–101.97) | |
| 2012 | 109.48 | 93.45 (74.86–112.04) | |
| 2013 | 74.90 | 105.97 (88.54–123.40) | |
| 2014 | 78.21 | 120.17 (103.71–136.63) | |
| 2015 | 108.43 | 136.27 (119.75–152.78) | |
| 2016 | 153.79 | 154.52 (135.70–173.35) | |
| 2017 | 190.95 | 175.22 (150.93–199.51) | |
| 2018 | 207.57 | 198.70 (165.56–231.84) | |
| 2019 | 253.41 | 225.32 (179.90–270.74) | |
| 2020 | 203.73 | 204.24 (129.54–278.94) | |
| 2020.5 | 225.34 | 213.79 (163.80–263.78) | |
| 2021 | 218.44 | 227.48 (171.83–283.13) | |
| Aboriginal or Torres Strait Islander women, 35-44 years | | | |
| 2011 | 25.62 | 22.26 (15.89–28.63) | |
| 2012 | 27.88 | 29.10 (22.03–36.17) | |
| 2013 | 21.59 | 38.04 (30.37–45.71) | |
| 2014 | 45.72 | 49.72 (41.59–57.85) | |
| 2015 | 81.19 | 64.99 (56.44–73.55) | |
| 2016 | 84.43 | 84.95 (75.50–94.41) | |
| 2017 | 141.27 | 111.04 (98.92–123.17) | |
| 2018 | 123.35 | 145.15 (126.83–163.47) | |
| 2019 | 184.28 | 189.73 (160.09–219.37) | |
| 2020 | 139.14 | 139.25 (91.05–187.45) | |
| 2020.5 | 121.75 | 119.42 (95.56–143.28) | |
| 2021 | 133.59 | 134.68 (106.60–162.75) | |

Table 1. Infectious syphilis notification rate for women aged 15–44 years, Australia,2011–2021, by Indigenous status and age group

| | Annual notification rate (per 100,000 population) | | |
|--|---|------------------------|--|
| Indigenous status/age group/year | Actual Fitted (95% confidence inte | | |
| Aboriginal or Torres Strait Islander women, 15-44 years | | | |
| 2011 | 56.23 | 39.91 (31.56–48.25) | |
| 2012 | 48.57 | 50.08 (41.32–58.83) | |
| 2013 | 39.99 | 62.84 (53.78–71.90) | |
| 2014 | 61.54 | 78.86 (69.41–88.30) | |
| 2015 | 105.76 | 98.96 (88.44–109.47) | |
| 2016 | 125.32 | 124.18 (110.81–137.56) | |
| 2017 | 187.55 | 155.83 (136.57–175.09) | |
| 2018 | 189.10 | 195.55 (166.34–224.76) | |
| 2019 | 242.81 | 245.40 (201.01–289.78) | |
| 2020 | 199.02 | 199.52 (138.14–260.89) | |
| 2020.5 | 224.16 | 212.66 (169.08–256.23) | |
| 2021 | 226.79 | 237.66 (186.67–288.65) | |
| Non-Indigenous women, 15-24 years | | | |
| 2011 | 0.56 | 0.36 (0.22–0.50) | |
| 2012 | 0.69 | 0.54 (0.36–0.71) | |
| 2013 | 0.62 | 0.80 (0.58–1.01) | |
| 2014 | 0.82 | 1.18 (0.92–1.44) | |
| 2015 | 1.03 | 1.74 (1.44–2.05) | |
| 2016 | 2.85 | 2.58 (2.21–2.95) | |
| 2017 | 5.18 | 3.82 (3.29–4.35) | |
| 2018 | 5.21 | 5.66 (4.75–6.58) | |
| 2019 | 8.13 | 8.38 (6.69–10.08) | |
| 2020 | 8.40 | 8.47 (5.64–11.30) | |
| 2020.5 | 8.00 | 6.72 (5.23-8.21) | |
| 2021 | 7.07 | 8.01 (6.15–9.86) | |
| Non-Indigenous women, 25-34 years | | | |
| 2011 | 1.76 | 0.97 (0.75–1.19) | |
| 2012 | 1.71 | 1.29 (1.05–1.54) | |
| 2013 | 1.60 | 1.72 (1.45–2.00) | |
| 2014 | 1.32 | 2.30 (2.00–2.59) | |
| 2015 | 2.63 | 3.06 (2.75–3.38) | |
| 2016 | 3.71 | 4.08 (3.74–4.43) | |
| 2017 | 5.42 | 5.45 (5.02–5.87) | |
| 2018 | 7.43 | 7.26 (6.62–7.90) | |
| 2019 | 10.29 | 9.68 (8.61–10.75) | |
| 2020 | 10.99 | 10.99 (8.84–13.13) | |
| 2020.5 | 10.89 | 11.05 (9.89–12.21) | |
| 2021 | 12.75 | 12.67 (11.29–14.05) | |
| Non-Indigenous women, 35-44 years | - | | |
| 2011 | 0.97 | 0.88 (0.65–1.10) | |
| 2012 | 1.67 | 1.10 (0.86–1.34) | |
| 2013 | 1.40 | 1.38 (1.13–1.63) | |

| | Annual notification rate (per 100,000 population) | | |
|-----------------------------------|---|----------------------------------|--|
| Indigenous status/age group/year | Actual | Fitted (95% confidence interval) | |
| 2014 | 1.27 | 1.73 (1.47–1.99) | |
| 2015 | 1.20 | 2.17 (1.91–2.43) | |
| 2016 | 3.04 | 2.72 (2.44–3.01) | |
| 2017 | 3.20 | 3.42 (3.06–3.78) | |
| 2018 | 5.06 | 4.29 (3.77–4.82) | |
| 2019 | 5.26 | 5.39 (4.57–6.20) | |
| 2020 | 6.85 | 6.85 (5.06–8.64) | |
| 2020.5 | 6.85 | 6.64 (5.70–7.58) | |
| 2021 | 7.30 | 7.39 (6.31–8.48) | |
| Non-Indigenous women, 15-44 years | | | |
| 2011 | 1.11 | 0.82 (0.61–1.02) | |
| 2012 | 1.38 | 1.07 (0.85–1.30) | |
| 2013 | 1.23 | 1.41 (1.17–1.65) | |
| 2014 | 1.15 | 1.85 (1.59–2.12) | |
| 2015 | 1.66 | 2.43 (2.13–2.74) | |
| 2016 | 3.23 | 3.20 (2.81–3.59) | |
| 2017 | 4.62 | 4.20 (3.62–4.79) | |
| 2018 | 5.98 | 5.53 (4.60-6.45) | |
| 2019 | 7.98 | 7.26 (5.79–8.74) | |
| 2020 | 8.83 | 8.85 (5.86–11.83) | |
| 2020.5 | 8.67 | 8.38 (6.47–10.28) | |
| 2021 | 9.22 | 9.52 (7.26–11.78) | |

| | Annual notification rate (per 100,000 population) | | |
|---|---|------------------------|--|
| Indigenous status/geographic region (remoteness)/year | Actual Fitted (95% confidence inter | | |
| Aboriginal or Torres Strait Islander women, major cities | | | |
| 2011 | 6.82 | 3.68 (1.25 -6.11) | |
| 2012 | 11.52 | 5.16 (2.29 -8.03) | |
| 2013 | 7.96 | 7.24 (3.92 –10.55) | |
| 2014 | 3.08 | 10.15 (6.43–13.87) | |
| 2015 | 4.46 | 14.24 (10.13–18.35) | |
| 2016 | 17.31 | 19.97 (15.18–24.76) | |
| 2017 | 29.40 | 28.01 (21.36–34.66) | |
| 2018 | 33.95 | 39.29 (28.16–50.41) | |
| 2019 | 73.73 | 55.11 (35.33–74.88) | |
| 2020 | 84.15 | 85.24 (41.58–128.91) | |
| 2020.5 | 117.31 | 92.22 (61.64–122.80) | |
| 2021 | 87.53 | 108.75 (71.37–146.12) | |
| Aboriginal or Torres Strait Islander women, inner and outer regional | | | |
| 2011 | 19.10 | 25.20 (16.30–34.11) | |
| 2012 | 39.20 | 34.27 (24.20-44.33) | |
| 2013 | 35.89 | 46.59 (35.45–57.73) | |
| 2014 | 60.93 | 63.34 (51.06–75.62) | |
| 2015 | 90.78 | 86.12 (71.82–100.41) | |
| 2016 | 125.35 | 117.08 (97.83–136.33) | |
| 2017 | 253.22 | 159.18 (128.96–189.40) | |
| 2018 | 185.43 | 216.41 (165.85–266.98) | |
| 2019 | 205.35 | 294.23 (209.63–378.83) | |
| 2020 | 156.36 | 157.61 (82.17–233.05) | |
| 2020.5 | 145.94 | 122.87 (82.74–163.00) | |
| 2021 | 120.12 | 140.55 (92.44–188.65) | |
| Aboriginal or Torres Strait Islander women, remote and very remote | | | |
| 2011 | 210.54 | 128.86 (93.52–164.19) | |
| 2012 | 131.05 | 156.28 (120.36–192.20) | |
| 2013 | 105.58 | 189.54 (153.42–225.67) | |
| 2014 | 171.13 | 229.88 (193.03–266.73) | |
| 2015 | 329.83 | 278.81 (238.47–319.14) | |
| 2016 | 337.66 | 338.14 (287.95–388.34) | |
| 2017 | 370.72 | 410.10 (340.26–479.95) | |
| 2018 | 518.98 | 497.38 (395.63–599.14) | |
| 2019 | 683.60 | 603.24 (454.79–751.69) | |
| 2020 | 542.44 | 540.95 (309.69–772.22) | |
| 2020.5 | 626.33 | 665.00 (477.76–852.24) | |

Table 2. Infectious syphilis notification rate for women aged 15–44 years, Australia,2011–2021, by Indigenous status and geographic location

| 2021 | 772.93 | 736.20 (519.22–953.17) |
|--|--------|------------------------|
| Non-Indigenous women, major cities | | |
| 2011 | 1.10 | 0.80 (0.59–1.00) |
| 2012 | 1.39 | 1.06 (0.83–1.29) |
| 2013 | 1.20 | 1.41 (1.16–1.66) |
| 2014 | 1.18 | 1.88 (1.61–2.15) |
| 2015 | 1.71 | 2.50 (2.20–2.80) |
| 2016 | 3.53 | 3.33 (2.95–3.72) |
| 2017 | 5.04 | 4.44 (3.87–5.01) |
| 2018 | 6.08 | 5.91 (4.99–6.83) |
| 2019 | 8.42 | 7.87 (6.37–9.38) |
| 2020 | 9.09 | 9.10 (6.29–11.92) |
| 2020.5 | 8.94 | 8.69 (6.90–10.48) |
| 2021 | 9.70 | 9.94 (7.79–12.08) |
| Non-Indigenous women, inner and outer regional | | |
| 2011 | 1.03 | 0.66 (0.43–0.88) |
| 2012 | 1.22 | 0.87 (0.62–1.12) |
| 2013 | 1.31 | 1.16 (0.88–1.44) |
| 2014 | 0.94 | 1.54 (1.24–1.85) |
| 2015 | 1.51 | 2.05 (1.73–2.38) |
| 2016 | 2.18 | 2.73 (2.38–3.09) |
| 2017 | 3.32 | 3.64 (3.18-4.09) |
| 2018 | 5.78 | 4.84 (4.15–5.53) |
| 2019 | 6.63 | 6.44 (5.30–7.58) |
| 2020 | 8.19 | 8.21 (5.73–10.69) |
| 2020.5 | 7.43 | 6.95 (5.72–8.18) |
| 2021 | 7.67 | 7.90 (6.45–9.35) |
| Non-Indigenous women, remote and very remote | | |
| 2011 | 2.77 | 2.34 (0.17–4.51) |
| 2012 | 2.79 | 2.37 (0.54-4.20) |
| 2013 | 1.40 | 2.40 (0.87–3.93) |
| 2014 | 2.87 | 2.44 (1.12–3.75) |
| 2015 | 1.47 | 2.47 (1.22–3.72) |
| 2016 | 3.02 | 2.50 (1.13–3.87) |
| 2017 | 1.55 | 2.54 (0.90-4.18) |
| 2018 | 3.18 | 2.57 (0.55-4.59) |
| 2019 | 3.25 | 2.61 (0.15–5.07) |
| 2020 | 3.33 | 3.59 (-3.31–10.49) |
| 2020.5 | 13.32 | 7.65 (2.04–13.27) |
| 2021 | 5.18 | 7.99 (1.93–14.04) |

| | Annual notification rate (per 100,000 population) | | |
|---|---|--------------------------|--|
| Indigenous status/state or territory/year | Actual Fitted (95% confidence interval) | | |
| Aboriginal or Torres Strait Islander women, | | | |
| NSW | | | |
| 2011 | 1.94 | 2.40 (0.28–4.53) | |
| 2012 | 5.68 | 2.97 (0.75–5.20) | |
| 2013 | 5.56 | 3.68 (1.40–5.96) | |
| 2014 | 3.62 | 4.55 (2.25–6.84) | |
| 2015 | 1.77 | 5.62 (3.30–7.95) | |
| 2016 | 5.21 | 6.96 (4.43–9.49) | |
| 2017 | 10.27 | 8.61 (5.39–11.82) | |
| 2018 | 3.36 | 10.64 (5.97–15.32) | |
| 2019 | 21.46 | 13.17 (6.05–20.28) | |
| 2020 | 25.87 | 26.48 (6.25-46.70) | |
| 2020.5 | 51.74 | 37.40 (21.70–53.09) | |
| 2021 | 33.17 | 42.07 (23.72–60.41) | |
| Aboriginal or Torres Strait Islander women, | | | |
| NT | | | |
| 2011 | 82.94 | 47.69 (16.44–78.94) | |
| 2012 | 23.47 | 71.46 (32.72–110.20) | |
| 2013 | 17.45 | 107.07 (59.96–154.18) | |
| 2014 | 149.84 | 160.43 (102.95–217.91) | |
| 2015 | 382.03 | 240.38 (165.02–315.74) | |
| 2016 | 552.36 | 360.18 (244.40-475.95) | |
| 2017 | 621.50 | 539.68 (335.25-744.10) | |
| 2018 | 784.86 | 808.63 (430.41–1186.85) | |
| 2019 | 710.64 | 1211.62 (516.47–1906.78) | |
| 2020 | 650.21 | 654.24 (67.68–1240.81) | |
| 2020.5 | 584.09 | 512.96 (196.22-829.71) | |
| 2021 | 538.17 | 614.73 (216.94–1012.51) | |
| Aboriginal or Torres Strait Islander women, | | | |
| Qld | | | |
| 2011 | 149.74 | 119.00 (93.84–144.15) | |
| 2012 | 148.86 | 133.39 (109.80–156.99) | |
| 2013 | 113.30 | 149.53 (127.69–171.38) | |
| 2014 | 138.74 | 167.62 (147.20–188.05) | |
| 2015 | 165.03 | 187.90 (167.49–208.32) | |
| 2016 | 179.93 | 210.64 (187.37–233.91) | |
| 2017 | 322.38 | 236.12 (206.20–266.05) | |
| 2018 | 256.71 | 264.69 (224.23–305.15) | |
| 2019 | 293.62 | 296.72 (241.91–351.53) | |

Table 3. Infectious syphilis notification rate for women aged 15–44 years, Australia,2011–2021, by Indigenous status and state/territory

| 2020 | 179.73 | 179.88 (112.43–247.34) |
|---|--------|------------------------|
| 2020.5 | 183.48 | 180.18 (137.99–222.37) |
| 2021 | 187.96 | 190.27 (143.66–236.87) |
| Aboriginal or Torres Strait Islander women, | | |
| SA | | |
| 2011 | 22.83 | 15.60 (4.36–26.84) |
| 2012 | 22.46 | 21.39 (8.26–34.52) |
| 2013 | 22.10 | 29.32 (14.34–44.30) |
| 2014 | 10.79 | 40.19 (23.56–56.83) |
| 2015 | 63.42 | 55.10 (37.03–73.16) |
| 2016 | 52.26 | 75.53 (55.56–95.49) |
| 2017 | 164.24 | 103.53 (78.55–128.52) |
| 2018 | 161.45 | 141.93 (103.66–180.19) |
| 2019 | 157.54 | 194.55 (129.09–260.01) |
| 2020 | 153.76 | 156.81 (49.27–264.35) |
| 2020.5 | 192.20 | 125.11 (74.05–176.16) |
| 2021 | 112.57 | 143.83 (82.64–205.02) |
| Aboriginal or Torres Strait Islander women, | | |
| Vic | | |
| 2011 | 8.40 | 3.82 (-0.03-7.67) |
| 2012 | 0.00 | 6.06 (0.82–11.30) |
| 2013 | 8.14 | 9.60 (2.65–16.56) |
| 2014 | 8.03 | 15.23 (6.28–24.17) |
| 2015 | 15.79 | 24.14 (13.06–35.23) |
| 2016 | 46.88 | 38.28 (24.94–51.61) |
| 2017 | 91.72 | 60.68 (43.87–77.49) |
| 2018 | 97.13 | 96.21 (69.56–122.86) |
| 2019 | 130.97 | 152.53 (99.37–205.69) |
| 2020 | 28.41 | 27.00 (-11.31–65.31) |
| 2020.5 | 42.61 | 73.60 (41.29–105.91) |
| 2021 | 110.54 | 96.15 (52.42–139.87) |
| Aboriginal or Torres Strait Islander women, | | |
| WA | | |
| 2011 | 32.66 | 17.47 (9.01–25.93) |
| 2012 | 18.54 | 25.73 (15.19–36.28) |
| 2013 | 27.62 | 37.90 (25.07–50.74) |
| 2014 | 45.61 | 55.83 (40.55–71.11) |
| 2015 | 129.98 | 82.24 (64.13–100.35) |
| 2016 | 97.43 | 121.14 (98.30–143.97) |
| 2017 | 138.64 | 178.44 (144.59–212.28) |
| 2018 | 186.33 | 262.84 (204.16-321.52) |
| 2019 | 518.50 | 387.16 (279.65–494.67) |
| 2020 | 519.42 | 520.47 (299.39–741.55) |
| 2020.5 | 673.62 | 646.73 (471.46-821.99) |

| 2021 | 759.94 | 785.80 (563.10–1008.50) |
|---------------------------|--------|-------------------------|
| Non-Indigenous women, NSW | | |
| 2011 | 0.77 | 0.55 (0.33–0.77) |
| 2012 | 1.04 | 0.72 (0.48–0.96) |
| 2013 | 1.02 | 0.94 (0.68–1.20) |
| 2014 | 1.15 | 1.23 (0.96–1.50) |
| 2015 | 1.00 | 1.61 (1.32–1.90) |
| 2016 | 1.51 | 2.10 (1.77–2.44) |
| 2017 | 2.00 | 2.75 (2.29–3.21) |
| 2018 | 4.02 | 3.59 (2.86–4.32) |
| 2019 | 6.00 | 4.70 (3.51–5.88) |
| 2020 | 5.68 | 5.71 (3.34-8.09) |
| 2020.5 | 5.30 | 4.59 (3.27–5.91) |
| 2021 | 4.65 | 5.16 (3.60–6.72) |
| Non-Indigenous women, NT | | |
| 2011 | 0.00 | 0.27 (-0.43–0.96) |
| 2012 | 2.65 | 0.41 (-0.49–1.32) |
| 2013 | 0.00 | 0.63 (-0.52–1.79) |
| 2014 | 0.00 | 0.97 (-0.45–2.39) |
| 2015 | 0.00 | 1.49 (-0.22–3.19) |
| 2016 | 0.00 | 2.28 (0.22-4.35) |
| 2017 | 2.57 | 3.50 (0.66–6.35) |
| 2018 | 15.51 | 5.37 (0.43–10.31) |
| 2019 | 2.61 | 8.24 (-1.41–17.88) |
| 2020 | 10.48 | 10.78 (-8.48–30.04) |
| 2020.5 | 10.48 | 5.12 (-2.00–12.24) |
| 2021 | 2.66 | 6.06 (-2.74–14.85) |
| Non-Indigenous women, Qld | | |
| 2011 | 1.34 | 1.07 (0.69–1.44) |
| 2012 | 2.41 | 1.39 (0.98–1.80) |
| 2013 | 1.40 | 1.82 (1.38–2.25) |
| 2014 | 2.36 | 2.37 (1.92–2.82) |
| 2015 | 1.92 | 3.09 (2.62–3.56) |
| 2016 | 3.18 | 4.03 (3.50-4.57) |
| 2017 | 4.82 | 5.26 (4.52-6.00) |
| 2018 | 6.83 | 6.86 (5.69-8.03) |
| 2019 | 10.93 | 8.95 (7.02–10.88) |
| 2020 | 12.74 | 12.82 (8.76–16.87) |
| 2020.5 | 12.74 | 11.14 (8.83–13.44) |
| 2021 | 11.45 | 12.55 (9.87–15.23) |
| Non-Indigenous women, SA | | |
| 2011 | 0.00 | 0.12 (-0.02–0.26) |
| 2012 | 0.63 | 0.18 (0.00–0.37) |
| 2013 | 0.00 | 0.29 (0.05–0.53) |

| 2014 | 0.00 | 0.45 (0.14–0.75) |
|---------------------------|-------|---------------------|
| 2015 | 1.25 | 0.69 (0.32–1.07) |
| 2016 | 0.94 | 1.08 (0.64–1.53) |
| 2017 | 1.88 | 1.69 (1.12–2.25) |
| 2018 | 2.81 | 2.63 (1.72–3.54) |
| 2019 | 3.72 | 4.10 (2.33–5.88) |
| 2020 | 3.08 | 2.96 (0.18-5.74) |
| 2020.5 | 1.23 | 3.92 (2.18-5.67) |
| 2021 | 6.21 | 4.91 (2.65–7.18) |
| Non-Indigenous women, Vic | | |
| 2011 | 1.71 | 1.18 (0.75–1.61) |
| 2012 | 1.76 | 1.58 (1.10-2.06) |
| 2013 | 1.89 | 2.12 (1.59–2.65) |
| 2014 | 1.13 | 2.83 (2.25–3.41) |
| 2015 | 2.85 | 3.79 (3.13-4.45) |
| 2016 | 6.34 | 5.07 (4.21-5.93) |
| 2017 | 9.29 | 6.78 (5.49-8.08) |
| 2018 | 9.15 | 9.08 (6.98–11.17) |
| 2019 | 10.56 | 12.14 (8.72–15.57) |
| 2020 | 12.35 | 12.35 (6.66–18.05) |
| 2020.5 | 9.91 | 9.92 (6.81–13.03) |
| 2021 | 11.29 | 11.28 (7.58–14.97) |
| Non-Indigenous women, WA | | |
| 2011 | 1.46 | 0.49 (0.22–0.76) |
| 2012 | 0.20 | 0.67 (0.35-0.98) |
| 2013 | 1.18 | 0.91 (0.55–1.27) |
| 2014 | 0.20 | 1.24 (0.84–1.63) |
| 2015 | 1.17 | 1.69 (1.26–2.11) |
| 2016 | 3.13 | 2.30 (1.82–2.77) |
| 2017 | 2.56 | 3.13 (2.52–3.73) |
| 2018 | 4.53 | 4.26 (3.33-5.19) |
| 2019 | 6.09 | 5.80 (4.22–7.37) |
| 2020 | 7.41 | 7.39 (4.06–10.73) |
| 2020.5 | 15.21 | 15.64 (13.04–18.24) |
| 2021 | 18.98 | 18.78 (15.56–21.99) |

Table 4. Numbers and notification rate of notifications of congenital syphilis, Australia,2011–2021, by Indigenous status

| | Number of notifications | | | tion rate 0 live births) |
|------|---|---|--|-----------------------------|
| Year | Aboriginal and Torres Strait Non-Indigenous Islander people people* | | Aboriginal and Torres Strait Islander people | Non-Indigenous people* |
| 2011 | 3 | 3 | 17.0 | 1.1 |
| 2012 | 0 | 0 | 0.0 | 0.0 |
| 2013 | 4 | 3 | 21.8 | 1.0 |
| 2014 | 3 | 0 | 16.9 | 0.0 |
| 2015 | 2 | 1 | 10.8 | 0.3 |
| 2016 | 1 | 1 | 5.4 | 0.3 |
| 2017 | 5 | 3 | 24.5 | 1.0 |
| 2018 | 4 | 5 | 18.2 | 1.7 |
| 2019 | 1 | 3 | 4.6 | 1.1 |
| 2020 | 8 | 9 | 36.3 | 3.3 |
| 2021 | 9 | 6 | 38.3 | 2.1 |

* Includes two cases with unknown Indigenous status.

STROBE Statement: checklist of items that should be included in reports of observational studies*

| | Item No | Recommendation | Page No |
|------------------|---------|--|------------|
| Title and | 1 | (<i>a</i>) Indicate the study's design with a commonly used term in the title | 1 |
| abstract | | or the abstract | |
| | | (b) Provide in the abstract an informative and balanced summary of | 1 |
| | | what was done and what was found | |
| Introduction | | | |
| Background/ratio | 2 | Explain the scientific background and rationale for the investigation | 2-3 |
| nale | | being reported | |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 3 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 3 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of | 3 |
| C | | recruitment, exposure, follow-up, and data collection | |
| Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and | 3-4 |
| - | | methods of selection of participants. Describe methods of follow-up | |
| | | Case-control study—Give the eligibility criteria, and the sources and | |
| | | methods of case ascertainment and control selection. Give the rationale | |
| | | for the choice of cases and controls | |
| | | Cross-sectional study—Give the eligibility criteria, and the sources | |
| | | and methods of selection of participants | |
| | | (b) Cohort study—For matched studies, give matching criteria and | |
| | | number of exposed and unexposed | |
| | | <i>Case-control study</i> —For matched studies, give matching criteria and | |
| X 7 • 11 | 7 | the number of controls per case | - |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential | 4 |
| | | confounders, and effect modifiers. Give diagnostic criteria, if applicable | |
| Data sources/ | 8* | For each variable of interest, give sources of data and details of | 3-4 |
| measurement | 0 | methods of assessment (measurement). Describe comparability of | 5-4 |
| measurement | | assessment methods if there is more than one group | |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4-5 |
| Study size | 10 | Explain how the study size was arrived at | n/a |
| Quantitative | 11 | Explain how quantitative variables were handled in the analyses. If | 4-5 |
| variables | | applicable, describe which groupings were chosen and why | |
| Statistical | 12 | (<i>a</i>) Describe all statistical methods, including those used to control for | 4-5 |
| methods | | confounding | |
| | | (b) Describe any methods used to examine subgroups and interactions | 5 |
| | | (c) Explain how missing data were addressed | n/a |
| | | (d) Cohort study—If applicable, explain how loss to follow-up was | n/a |
| | | addressed | |
| | | Case-control study—If applicable, explain how matching of cases and | |
| | | controls was addressed | |
| | | Cross-sectional study—If applicable, describe analytical methods | |
| | | taking account of sampling strategy | |
| | | (<u>e</u>) Describe any sensitivity analyses | 4 |
| Results | | | <u> </u> |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers | 5-7 |
| | | potentially eligible, examined for eligibility, confirmed eligible, | |
| | | included in the study, completing follow-up, and analysed | |
| | | (b) Give reasons for non-participation at each stage | n/a |
| | | (c) Consider use of a flow diagram | n/a |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, | n/a |
| | | social) and information on exposures and potential confounders | |

| | | (b) Indicate number of participants with missing data for each variable of interest | n/a |
|-------------------|-----|---|-----|
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | n/a |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time | n/a |
| | | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure | n/a |
| | | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures | n/a |
| Main results | 16 | (<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 5-7 |
| | | (b) Report category boundaries when continuous variables were categorized | n/a |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 5-7 |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | n/a |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 7 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 9 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 9 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | n/a |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | n/a |

* The pages numbers in this table refer to the submitted manuscript, not to the published article or its Supporting Information file.